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The ELR+-CXCL chemokines have been described typically as potent chemoattractants and activators of neu-
trophils during the acute phase of inflammation. Their role in atherosclerosis, a chronic inflammatory vascu-
lar disease, has been largely unexplored. Using a mouse model of atherosclerosis, we found that CXCL5 expres-
sion was upregulated during disease progression, both locally and systemically, but was not associated with 
neutrophil infiltration. Unexpectedly, inhibition of CXCL5 was not beneficial but rather induced a significant 
macrophage foam cell accumulation in murine atherosclerotic plaques. Additionally, we demonstrated that 
CXCL5 modulated macrophage activation, increased expression of the cholesterol efflux regulatory protein 
ABCA1, and enhanced cholesterol efflux activity in macrophages. These findings reveal a protective role for 
CXCL5, in the context of atherosclerosis, centered on the regulation of macrophage foam cell formation.
Introduction
Atherosclerosis is a disease in which chronic inflammation plays a 
fundamental role. Activated macrophages accumulate in athero-
sclerotic lesions and contribute not only to the initiation phase but 
also to the development, progression, and the complication stages 
of the disease (1). Chemokines, cytokines that attract and acti-
vate leukocytes, are implicated in all stages of atherosclerosis and 
as such have been proposed as potential therapeutic targets (2). 
Substantial evidence has incriminated the CCL2 and CX3CL1 
chemokines, which recruit and stimulate monocytes/macro-
phages, in the pathogenesis of atherosclerosis (1).
Although it is known that ELR+-CXCL chemokines, in particu-
lar CXCL1 and CXCL2, are induced during atherosclerosis (3–5), 
their exact functional contribution to the development of the 
pathology has not been ascertained. Indeed, while the ELR+-CXCL 
chemokines have been identified as potent and specific attrac-
tants of neutrophils in acute inflammation (2), whether this effect 
underlies their role in chronic diseases such as atherosclerosis is 
uncertain. One study, however, has put forward the hypothesis 
that the ELR+-CXCL receptor CXCR2 is involved in the accumula-
tion of macrophages in advanced atherosclerotic plaques leading 
to lesion progression (6). The fact that CXCL1 alone has a similar 
but less pronounced effect (7) points toward the implication of 
alternative CXCR2 ligands in the pathogenesis of atherosclerosis. 
However, CXCL5, which has recently been shown to participate in 
obesity-induced insulin resistance (8), has received little attention 
in other obesity-related pathologies. We therefore set ourselves to 
investigate its expression and function in atherosclerosis.
Results and Discussion
Upregulation of CXCL5 in atherosclerosis. In atherosclerosis-prone Apoe–/– 
mice fed a Western diet (WD), CXCL5 expression was upregulated 
in both aorta and plasma and remained elevated up to 48 weeks 
(Figure 1A). As previously observed (3, 5), expression of CXCL1 and 
CXCL2 was also increased as disease progressed (Supplemental 
Figure 1A; supplemental material available online with this article; 
doi:10.1172/JCI66580DS1). This rise in CXCL5 expression, unlike 
the rise in CXCL1 and CXCL2, was also evident in Apoe–/– mice fed a 
chow diet (CD) for 12 weeks (Figure 1, B and C), despite a lower ele-
vation of plasma triglycerides and cholesterol levels (Supplemental 
Figure 1B). Of note, the level of CXCL5 induction (mRNA and pro-
tein) was similar with both diets in Apoe–/– mice, which suggests that 
CXCL5 expression is induced once the cholesterol levels reach a mild 
hypercholesterolemia but is not further increased if the cholesterol 
level goes above this threshold. Further analysis of the aortic arch 
region, which is more prone to develop atherosclerotic plaques, com-
pared with the thoracic aortas of Apoe–/– mice fed a CD, confirmed 
that CXCL5, but not CXCL1 and CXCL2, expression was specifically 
upregulated in susceptible regions (9-fold increase) (Supplemental 
Figure 1C). These data suggest that the regulation of CXCL5 expres-
sion is distinct from that of CXCL1 and CXCL2 and that CXCL5 
might play an essential role in atherosclerosis.
Endothelial cells are a source of CXCL5 in atherogenic conditions. Similar 
to what we observed in Apoe–/– mice, there was an increase of Cxcl5 
expression in the aortas of WT animals treated with a WD (Figure 
1D), a mouse model that develops mild hypercholesterolemia-in-
duced endothelial dysfunction but without monocyte infiltration, 
foam macrophage accumulation, and atherosclerotic plaque for-
mation. This intimates that CXCL5 comes from endothelial cells 
rather than the atheromatous plaque. Accordingly, activated mac-
rophages and cholesterol-loaded macrophages in vitro did not 
produce CXCL5 (data not shown). In human endothelial cells, in 
which the combinatory treatment of oxidized LDL or IL-1β and 
proatherogenic (low) laminar shear stress (LSS) leads to a similar 
dysfunction, an increase of expression of the human homolog of 
CXCL5, CXCL6 (9), was seen compared with that in endothelial 
cells subjected to physiological (high) LSS (Figure 1, E–G). The 
expression of CXCL8, the alleged ELR+-CXCL prototype chemok-
ine in humans, remained unchanged (Figure 1, E and F).
Inhibition of CXCL5 is associated with macrophage foam cell accumulation 
in atherosclerotic plaques. Despite the potent neutrophil chemotaxis of 
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CXCL5 in acute inflammatory models (2, 10, 11), the rise in CXCL5 
levels observed in Apoe–/– mice fed a WD was not accompanied by 
neutrophil infiltration within the atheromatous plaques (Supple-
mental Figure 1D). Moreover, blocking CXCL5 using a specific 
mAb did not diminish lesion size (Supplemental Figure 2, A and 
B) or the infiltration of monocytes/macrophages (Figure 2, E, G, 
and I, and Supplemental Figure 2C), as has been observed when 
blocking CXCL1 and CXCR2 in murine models of atherosclerosis 
(6, 7). Instead, we observed an accumulation of foam cells in both 
the brachiocephalic artery and the aortic root lesions (Figure 2B and 
Supplemental Figure 2E) corresponding to macrophages (Figure 2, 
C, E, G, and I, and Supplemental Figure 2C) with increased lipid 
storage capacity (Figure 2, C, F, H, and J, and Supplemental Fig-
ure 2D). This was accompanied by a significant reduction of col-
lagen content (Figure 2, A and D, and Supplemental Figure 2, E and 
F), suggesting a role for CXCL5 in both macrophage activity and 
plaque stability. The kinin B1 receptor has been recently described 
to regulate CXCL5 expression (10). This specific CXCL5 reduction 
also could be observed in ApoE-B1R double-knockout mice (Sup-
plemental Figure 3A) and was associated with higher macrophage 
foam cell accumulation in atherosclerotic plaques (Supplemental 
Figure 3, D–G). These observations corroborate the role of CXCL5 
in atherosclerosis, without the use of blocking Abs, and in a more 
chronic state with mild hypercholesterolemia (after 60 weeks of 
CD). However, neither of the 2 models had a change in monocyto-
sis or plasma cholesterol levels (Table 1 and Supplemental Figure 
3, B and C), suggesting that CXCL5 limits macrophage foam cell 
accumulation through a different route. In the context of CXCL5 
inhibition, it was recently described that a subsequential increase of 
CXCL1 and CXCL2 as well as their upstream regulator IL-17 could 
lead to a greater recruitment of leukocytes or leukocytosis (11, 12). 
Moreover, CXCL1 and CXCL2 have both been implicated in leu-
kocyte mobilization (13, 14) and CXCL1 has been implicated as a 
potent monocyte chemoattractant in atherosclerosis (15). However, 
this indirect effect could not account for our results, since neither 
expression levels of CXCL1, CXCL2, and IL-17 nor monocytosis 
were affected here (Table 1, Supplemental Figure 3A, and Supple-
mental Figure 5). Importantly, we demonstrated that exogenous 
CXCL5 diminished peritoneal macrophage (PM) foam cell forma-
tion in vivo (Figure 3A and Supplemental Figure 4). Taken together, 
these findings intimate that CXCL5 can alter the phenotype of mac-
rophages in atherosclerosis by preventing foam cell formation.
CXCL5 regulates macrophage activation. It is well described that the 
T cell–adaptive response participates in atherogenesis (1). Because 
T cells are known to modulate macrophages, we asked whether 
Figure 1
Upregulation of CXCL5 in atherosclerosis. (A) Assessment of CXCL5 mRNA (blue triangles) and protein (red triangles) expression during the 
progression of atherosclerosis in aortas and plasma of Apoe–/– mice, respectively (n = 6–8 per time point), fed a WD for the indicated time. 
Apoe–/– mice fed a CD were used as controls. (B) Aortic Cxcl1, Cxcl2, and Cxcl5 mRNA and (C) plasma CXCL5 protein expression was mea-
sured in Apoe–/– mice fed CD or WD for 12 weeks (n = 8 mice per group). WT mice fed CD for 12 weeks were used as controls. (D) Assessment 
of Cxcl5 mRNA in aortas of WT mice (n = 6–8 per time point) fed WD. WT mice fed CD were used as controls. (E–G) HUVECs were subjected 
to high or low LSS and stimulated with (E) oxidized LDL (n = 3) or (F and G) IL-1β (n = 6). (E and F) CXCL8 and CXCL6 mRNA expression and 
(G) protein release were determined. (A–G) mRNA and protein levels were measured by qPCR and ELISA, respectively. Data are mean ± SEM. 
*P < 0.05, **P < 0.01, ***P < 0.001.
Table 1
Anti-CXCL5 Ab does not change peripheral blood parameters  
in Apoe–/– mice
Models Total cholesterol Monocytes CXCL1 CXCL2
 (mg/dl) (% of wbc) (pg/ml) (pg/ml)
Isotype IgG 739.2 ± 62.4 7.2 ± 0.7 1,154 ± 104 103 ± 24
CXCL5 Ab 840.1 ± 133.9 6.9 ± 0.4 1,033 ± 88 107 ± 12
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blocking CXCL5 in atherosclerotic mice could have affected the 
overall profile of cytokines typically secreted by T cells. Plasma 
levels of cytokines produced by Th1 (IFN-γ and IL-2), Th2 (IL-4), 
Th17 (IL-17), or Treg (IL-10) cells were unchanged (Supplemental 
Figure 5). However, circulating levels of IL-6, a cytokine mainly 
secreted by activated macrophages, were significantly lower in 
Apoe–/– mice treated with anti-CXCL5 Ab (Figure 2K). In addition, 
a gene expression correlation analysis, based upon a microarray 
data set of age-dependent aorta transcriptomes from WT and 
Apoe–/– mice, revealed that among all cytokines only IL-6 was 
positively and highly correlated with CXCL5 profile expression 
(r = 0.76) (Supplemental Table 1). Moreover, a biological func-
tions analysis of these correlated genes revealed that, besides 
the expected immune function genes, the expression of CXCL5 
in atherosclerosis was particularly associated with macrophage 
activation genes (Supplemental Table 2, P = 1.47 × 10–7). These 
observations strongly suggest that CXCL5 directly acts on macro-
phages rather than on the T cell–adaptive response. Indeed, stim-
ulation of primary bone marrow–derived macrophages (BMDMs) 
and PMs with CXCL5 induced an augmentation of Il6 expression, 
an effect that was even greater in cholesterol-loaded macrophages 
(Figure 3B and Supplemental Figure 6, B and C). Thus, in addition 
to the well-described neutrophil arrest and recruitment-associated 
functions of ELR+-CXCL chemokines, herein we demonstrate that 
CXCL5 specifically modulates macrophage activation, particularly 
by upregulating IL-6 expression.
Activation of the CXCL5/CXCR2 pathway induces ABCA1 expression 
and cholesterol efflux in macrophages. Since in our experiments the pri-
mary target of CXCL5 appeared to be macrophages, we investigated 
whether the effects of CXCL5 on foam cell formation observed in 
vivo were due to a direct action. In vitro, CXCL5 was indeed able 
to reduce intracellular lipid accumulation in macrophages (Figure 
3C). We speculated that this might be attributable to a decrease 
of cholesterol uptake or/and an increase of cholesterol efflux. In 
BMDMs and PMs, CXCL5 treatment significantly upregulated 
the expression of Abca1, a transporter that mediates the efflux of 
cholesterol (Figure 3, D and E, and Supplemental Figure 6D). In 
contrast, the expression of other cholesterol trafficking genes, such 
Figure 2
Blockade of CXCL5 is associated with macrophage foam cell accumulation in atherosclerotic plaques. Apoe–/– mice were fed a WD and treated 
with either IgG isotype control (IgG) or anti-CXCL5 Ab (CXCL5 Ab) for 12 weeks. (A and B) Representative images from brachiocephalic artery 
lesions of picrosirius red staining for collagen detection. Black asterisks indicate some foam cells. (C) Representative images of macrophages 
(Mac2 immunostaining) containing lipid droplets (adipophilin immunostaining) from anti-CXCL5 Ab-treated brachiocephalic artery lesions. 
White asterisks indicate double-positive cells. (D–F) Quantification of (D) sirius red staining, (E) Mac2, and (F) adipophilin immunostaining in 
brachiocephalic artery lesions. Representative images from aortic root lesions of (G) Mac2 and (H) adipophilin immunostaining. Quantification 
of (I) Mac2 and (J) adipophilin immunostaining in aortic root lesions. (K) Quantification of plasma IL-6 by ELISA. Data in D–F and I–K represent 
mean ± SEM. n =7–8. **P < 0.01. Scale bars: 100 μm (A, G, and H); 50 μm (B); 10 μm (C).
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as Msr1, Cd36, and Abcg1, was not affected. Accordingly, in the in 
vivo gene expression correlation study mentioned earlier, Abca1 was 
highly correlated with CXCL5 expression (r = 0.78, Supplemental 
Table 1). ABCA1 upregulation was even more pronounced in cho-
lesterol-loaded macrophages treated with CXCL5 (Figure 3, D and 
E, and Supplemental Figure 6D). Additionally, stimulation with 
CXCL5 induced ABCA1 expression in alternatively activated (M2) 
macrophages but not in classically activated (M1) macrophages 
(Figure 3G and Supplemental Figure 7, B and C). Accordingly, 
there is evidence to support that M2 macrophages are more sus-
ceptible to foam cell formation (16, 17). These observations suggest 
that in atherosclerotic lesions, in which macrophage heterogene-
ity is observed, several subtypes of macrophages can be targeted by 
CXCL5. Importantly, the induction of ABCA1 could be reversed, 
both by anti-CXCL5 Ab and by anti-CXCR2 Ab (Figure 3F, Supple-
mental Figure 6A, and Supplemental Figure 7C). Because IL-6 has 
been implicated in ABCA1 induction (18), we tested whether this 
was the case here. However, anti–IL-6 Ab treatment did not inhibit 
CXCL5-induced ABCA1 (Supplemental Figure 7A). Indeed, the fast 
induction of ABCA1 observed here does not support the implica-
Figure 3
CXCL5 modulates macrophage activation and induces ABCA1 expression and cholesterol efflux in macrophages. (A) Apoe–/– mice were fed a 
WD and treated with CXCL5 for 12 days. By flow cytometry, PMs (CD11b+CD115+) were gated and foam cells were identified as high forward 
scatter (FSChi) and high side scatter (SSChi) cells. Data are mean ± SEM. *P < 0.05. n = 3 animals per group. (B and D–G) BMDMs or (C and H) 
PMs were cholesterol loaded (gray bars) or not (white bars) with acLDL and treated with or without CXCL5 in vitro. (B) Macrophage activation 
was determined by Il6 mRNA expression in BMDMs using qPCR. n = 6. (C) Foam cell formation was assessed in cholesterol-loaded PMs as 
the percentage of Oil Red O–positive cells. Scale bar: 50 μm. n = 4. (D) Expression of genes involved in cholesterol trafficking was measured 
by qPCR in BMDMs. n = 6. (E) ABCA1 protein expression was measured by Western blotting in BMDMs. Lanes separated by a white line were 
run on the same gel but were noncontiguous. n = 3–5. (F) CXCL5-induced ABCA1 expression was blocked by anti-CXCL5 Ab and anti-CXCR2 
Ab in cholesterol-loaded BMDMs. n = 4. (G) Expression of CXCL5-induced Abca1 in naive (M0), classically activated (M1), and alternatively 
activated (M2) macrophages from BMDM was determined by qPCR. n = 4. (H) Cholesterol efflux was assessed in cholesterol-loaded PMs 
treated or not with CXCL5. n = 6. (I) Proposed mechanism of action for CXCL5 in atherosclerosis. EC, endothelial cell; Mac, macrophage. Data 
are mean ± SEM. *P < 0.05, **P < 0.01.
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toneal cell isolation. Macrophage foam cell formation was determined by 
flow cytometry and by staining of lipids with Oil Red O.
Cell stimulation. Using a cone and plate viscometer, HUVECs were exposed to 
steady unidirectional high (10 dyn/cm2) or low (2 dyn/cm2) LSS for 24 hours. 
Oxidized LDL (20 μg/ml, BTI) or IL-1β (10 ng/ml, Peprotech) was added for 
the last 4 hours or an additional 24 hours for treatment.
PMs or BMDMs were stimulated with CXCL5 (100 ng/ml, Peprotech) 
and cholesterol loaded or not with acLDL (20 μg/ml, BTI). In some exper-
iments, macrophages were also treated with CXCL5, CXCR2, IL-6, or con-
trol IgG Abs (20 μg/ml, 20 minutes prior to CXCL5 stimulation).
qPCR analysis was performed after 4 hours of treatment. ELISA and 
Western blotting were performed on supernatant collected at 24 to 48 
hours and on cell lysate collected at 24 hours. Macrophage foam cells were 
stained for lipids with Oil Red O.
Statistics. Data are expressed as mean ± SEM. Results were analyzed by 
2-tailed Student’s t test or 1-way ANOVA with Bonferroni post-hoc test for 
multiple comparisons as appropriate using GraphPad Prism software. A 
P value of less than 0.05 was considered statistically significant.
Study approval. All experiments followed United Kingdom legislation for 
the protection of animals and were approved by the Ethical Review Process 
of Queen Mary, University of London.
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tion of an indirect pathway through cytokine release but rather sug-
gests that the CXCL5/CXCR2 pathway regulates ABCA1 in a direct 
manner. Finally, we demonstrated that CXCL5 treatment produced 
an increase of cholesterol efflux in macrophages (Figure 3H). Alto-
gether these data demonstrate that CXCL5 induces ABCA1 expres-
sion and reduces the cholesterol content of macrophages.
To summarize, our findings show that, unlike other ELR+-CXCL 
chemokines (6, 7), the induction of CXCL5 plays a protective role 
in atherosclerosis (Figure 3I). It does so by limiting the cholesterol 
content of macrophages and therefore foam cell formation, a func-
tion that we believe has never been attributed to an ELR+-CXCL 
chemokine prior to this study. These findings strengthen the 
emerging concept that chemokines can regulate foam cell forma-
tion, as was recently proposed for CXCL4 (19). Additionally, these 
findings highlight the complex interplay between inflammation 
and atherosclerosis and support the notion that proinflammatory 
mediators of acute immune responses are not necessarily harmful 
in chronic inflammatory diseases (20, 21). This study encourages 
us to rethink ELR+-CXCL chemokines as important players of 
chronic inflammatory diseases, especially in light of their newly 
described role in macrophage regulation.
Methods
See Supplemental Methods for details.
Animal procedure. All mice were males on a C57BL/6 background. 6-week-
old Apoe–/– and WT mice were placed on a WD (21% fat, 0.2% cholesterol, 
Harlan Teklad) or remained on CD for the indicated time (see the legends 
for Figures 1 and 2). ELR+-CXCL chemokines were quantified from the aorta 
mRNA by qPCR, and plasma CXCL5 concentration was assessed by ELISA.
Additionally, Apoe–/– mice fed a WD were treated with a mouse CXCL5 
mAb (50 μg per mouse, i.p., every 72 hours, R&D Systems; ref. 22) or IgG 
isotype control for 12 weeks. Alternatively, Apoe–/–B1R–/– and Apoe–/–B1R+/+ 
mice were fed a CD for 60 weeks. The brachiocephalic artery and heart 
were fixed with 4% PFA and embedded in paraffin for histology and 
immunostaining analysis. Blood was collected for measurement of leuko-
cytes, lipids, cytokines, and chemokines.
In addition, Apoe–/– mice on WD were injected with CXCL5 (400 ng, i.p., 
every 72 hours, Peprotech). After 12 days, animals were sacrificed for peri-
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